Search

Your search keyword '"Goletti, Delia"' showing total 1,089 results
Start Over Author "Goletti, Delia"
1,089 results on '"Goletti, Delia"'

3. Target product profiles: tests for tuberculosis treatment monitoring and optimization/ Profils de produits cibles: essais pour le suivi et l'optimisation du traitement de la tuberculose/ Perfiles de productos objetivo: pruebas para el seguimiento y la optimizacion del tratamiento de la tuberculosis

Author

Gupta-Wright, Ankur, den Boon, Saskia, MacLean, Emily L., Cirillo, Daniela, Cobelens, Frank, Gillespie, Stephen H., Kohli, Mikashmi, Ruhwald, Morten, Savic, Rada, Brigden, Grania, Gidado, Mustapha, Goletti, Delia, Hanna, Debra, Hasan, Rumina, Hewison, Cathy, Koura, Kobto G., Lienhardt, Christian, Lungu, Patrick, McHugh, Timothy D., McKenna, Lindsay, Scott, Cherise, Scriba, Thomas, Sekaggya-Wiltshire, Christine, Kasaeva, Tereza, Zignol, Matteo, Denkinger, Claudia M., and Falzon, Dennis

Subjects
Cost benefit analysis -- Surveys, Tuberculosis -- Surveys, Public health -- Surveys, Cost benefit analysis, Health, World Health Organization -- Surveys
Abstract

The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics for tests for tuberculosis treatment monitoring and optimization. Tuberculosis treatment optimization refers to initiating or switching to an effective tuberculosis treatment regimen that results in a high likelihood of a good treatment outcome. The target product profiles also cover tests of cure conducted at the end of treatment. The development of the target product profiles was informed by a stakeholder survey, a cost-effectiveness analysis and a patient-care pathway analysis. Additional feedback from stakeholders was obtained by means of a Delphi-like process, a technical consultation and a call for public comment on a draft document. A scientific development group agreed on the final targets in a consensus meeting. For characteristics rated of highest importance, the document lists: (i) high diagnostic accuracy (sensitivity and specificity); (ii) time to result of optimally [less than or equal to] 2 hours and no more than 1 day; (iii) required sample type to be minimally invasive, easily obtainable, such as urine, breath, or capillary blood, or a respiratory sample that goes beyond sputum; (iv) ideally the test could be placed at a peripheral-level health facility without a laboratory; and (v) the test should be affordable to low- and middle-income countries, and allow wide and equitable access and scale-up. Use of these target product profiles should facilitate the development of new tuberculosis treatment monitoring and optimization tests that are accurate and accessible for all people being treated for tuberculosis. L'Organisation mondiale de la sante a elabore des profils de produits cibles contenant des cibles minimales et optimales pour les caracteristiques principales des essais destines au suivi et a l'optimisation du traitement de la tuberculose. L'optimisation du traitement de la tuberculose fait reference a l'instauration d'un regime de traitement efficace de la tuberculose ou a l'adoption d'un tel regime, avec une probabilite elevee d'obtenir de bons resultats therapeutiques. Les profils de produits cibles couvrent egalement les essais de guerison effectues a l'issue du traitement. Les profils de produits cibles ont ete elabores sur la base d'un sondage aupres des parties prenantes, d'une analyse cout-efficacite et d'une analyse du parcours de soins du patient. Des retours supplementaires des parties prenantes ont ete obtenus au moyen d'un processus cree selon la methode Delphi, d'une consultation technique et d'un appel a commentaires publics sur un projet de document. Un groupe d'elaboration scientifique s'est mis d'accord sur les objectifs finaux lors d'une reunion de concertation. En ce qui concerne les caracteristiques jugees les plus importantes, le document enumere ce qui suit: (i) une grande precision diagnostique (sensibilite et specificite); (ii) un delai ideal d'obtention des resultats [less than or equal to] 2 heures et au maximum de 1 jour; (iii) le type d'echantillon requis doit etre peu invasif et facile a obtenir, comme l'urine, l'haleine ou le sang capillaire, ou bien un echantillon respiratoire au-dela des expectorations; (iv) idealement, l'essai pourrait avoir lieu dans un etablissement de sante peripherique sans laboratoire ; et (v) l'essai devrait etre abordable pour les pays a revenu faible et intermediaire et permettre un acces large et equitable ainsi qu'une mise a l'echelle. L'utilisation de ces profils de produits cibles devrait faciliter la mise au point de nouveaux essais de surveillance et d'optimisation du traitement de la tuberculose qui soient precis et accessibles a toutes les personnes suivant un traitement pour la tuberculose. La Organizacion Mundial de la Salud ha elaborado perfiles de productos objetivo que contienen objetivos minimos y optimos para las caracteristicas principales de las pruebas de seguimiento y optimizacion del tratamiento de la tuberculosis. La optimizacion del tratamiento de la tuberculosis consiste en iniciar o cambiar a un regimen eficaz de tratamiento de la tuberculosis que ofrezca una alta probabilidad de un buen resultado terapeutico. Los perfiles de productos objetivo tambien abarcan las pruebas de curacion realizadas al final del tratamiento. La elaboracion de los perfiles de los productos objetivo se baso en una encuesta a las partes interesadas, un analisis de rentabilidad y un analisis de la via de atencion al paciente. Se obtuvo informacion adicional de las partes interesadas mediante un proceso tipo Delphi, una consulta tecnica y una convocatoria de comentarios publicos sobre un borrador del documento. Un grupo de desarrollo cientifico acordo los objetivos finales en una reunion de consenso. Para las caracteristicas clasificadas de mayor importancia, el documento enumera: (i) alta precision diagnostica (sensibilidad y especificidad); (ii) tiempo hasta el resultado de optimamente [less than or equal to] 2 horas y no mas de 1 dia; (iii) el tipo de muestra requerida debe ser minimamente invasiva, facil de obtener, como orina, aliento o sangre capilar, o una muestra respiratoria que vaya mas alla del esputo; (iv) idealmente la prueba podria realizarse en un centro sanitario periferico sin laboratorio; y (v) la prueba debe ser asequible para los paises de ingresos bajos y medios y permitir un acceso amplio y equitativo y su expansion. El uso de estos perfiles de producto objetivo deberia facilitar el desarrollo de pruebas nuevas de seguimiento y optimizacion del tratamiento de la tuberculosis que sean precisas y accesibles para todas las personas que reciben tratamiento antituberculoso. [phrase omitted], Introduction Tuberculosis continues to be a major cause of morbidity and mortality globally, despite being curable and preventable. In 2021, an estimated 10.6 million people had tuberculosis disease and 1.6 [...]

Published
2023
Full Text
View/download PDF

11. Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study

Author

Nalunjogi, Joanitah, Mucching-Toscano, Sergio, Sibomana, Jean Pierre, Centis, Rosella, D'Ambrosio, Lia, Alffenaar, Jan-Willem, Denholm, Justin, Blanc, François-Xavier, Borisov, Sergey, Danila, Edvardas, Duarte, Raquel, García-García, José-María, Goletti, Delia, Ong, Catherine W.M., Rendon, Adrian, Thomas, Tania A., Tiberi, Simon, van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista

Published
2023
Full Text
View/download PDF

12. Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19

Author

Arbous, M.S., van den Berg, B.M., Cannegieter, S., Cobbaert, C.M., van der Does, A., van Dongen, J.J.M., Eikenboom, J., Feltkamp, M.C.M., Geluk, A., Goeman, J.J., Giera, M., Hankemeier, T., Heemskerk, M.H.M., Hiemstra, P.S., Hokke, C.H., Janse, J.J., Jochems, S.P., Joosten, S.A., Kikkert, M., Lamont, L., Manniën, J., Ottenhoff, T.H.M., del Prado, M.R., Queralt Rosinach, N., Roestenberg, M., Roos, M., Roukens, A.H.E., Smits, H.H., Snijder, E.J., Staal, F.J.T., Trouw, L.A., Tsonaka, R., Verhoeven, A., Visser, L.G., de Vries, J.J.C., van Westerloo, D.J., Wigbers, J., van der Wijk, H.J., van Wissen, R.C., Wuhrer, M., Yazdanbakhsh, M., Zlei, M., Pierneef, Louise, van Hooij, Anouk, de Jong, Danielle, Tjon Kon Fat, Elisa M., van Meijgaarden, Krista E., Petruccioli, Elisa, Vanini, Valentina, Roukens, Anna H.E., Goletti, Delia, Corstjens, Paul L.A.M., Joosten, Simone A., and Geluk, Annemieke

Published
2023
Full Text
View/download PDF

13. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Greinix, Hildegard, Maertens, Johan, De Greef, Julien, Slavin, Monica, Spriet, Isabel, Hubacek, Petr, Bergeron, Anne, Cordonnier, Catherine, Kanerva, Jukka, Herbrecht, Raoul, Herrmann, Jean-Louis, Lanternier, Fanny, Bondeelle, Louise, Robin, Christine, Einsele, Hermann, Lehrnbecher, Thomas, Groll, Andreas, Maschmeyer, Georg, Lange, Christoph, von Lilienfeld-Toal, Marie, Pana, Dorothea, Roilides, Emmanuel, Kassa, Csaba, Averbuch, Diana, Engelhard, Dan, Cesaro, Simone, Mikulska, Malgorzata, Pagano, Livio, Castagnola, Elio, Compagno, Francesca, Goletti, Delia, Mesini, Alessio, Donnelly, Peter J, Styczynski, Jan, Botelho de Sousa, Aida, Aljurf, Mahmoud, de la Camara, Rafael, Navarro, David, Rovira, Montserrat, Franquet, Tomas, Garcia-Vidal, Carol, Ljungman, Per, Paukssen, Karlis, Ammann, Roland, Lamoth, Frédéric, Hirsch, Hans, Ritz, Nicole, Akova, Murat, Ceesay, Mansour, Warris, Adilia, Chemaly, Roy, and Donnelly, J Peter

Published
2022
Full Text
View/download PDF

14. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study

Author

Farroni, Chiara, Aiello, Alessandra, Picchianti-Diamanti, Andrea, Laganà, Bruno, Petruccioli, Elisa, Agrati, Chiara, Garbuglia, Anna Rosa, Meschi, Silvia, Lapa, Daniele, Cuzzi, Gilda, Petrone, Linda, Vanini, Valentina, Salmi, Andrea, Altera, Anna Maria Gerarda, Repele, Federica, Grassi, Germana, Bettini, Aurora, Vita, Serena, Mariano, Andrea, Damiani, Arianna, Infantino, Maria, Grossi, Valentina, Manfredi, Mariangela, Niccoli, Laura, Puro, Vincenzo, Rosa, Roberta Di, Salemi, Simonetta, Sesti, Giorgio, Scolieri, Palma, Bruzzese, Vincenzo, Benucci, Maurizio, Cantini, Fabrizio, Nicastri, Emanuele, and Goletti, Delia

Published
2022
Full Text
View/download PDF

17. Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay

Author

Aiello, Alessandra, Coppola, Andrea, Vanini, Valentina, Petrone, Linda, Cuzzi, Gilda, Salmi, Andrea, Altera, Anna Maria Gerarda, Tortorella, Carla, Gualano, Gina, Gasperini, Claudio, Scolieri, Palma, Beccacece, Alessia, Vita, Serena, Bruzzese, Vincenzo, Lorenzetti, Roberto, Palmieri, Fabrizio, Nicastri, Emanuele, and Goletti, Delia

Published
2022
Full Text
View/download PDF

19. Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis.

Author

Najafi-Fard, Saeid, Farroni, Chiara, Petrone, Linda, Altera, Anna Maria Gerarda, Salmi, Andrea, Vanini, Valentina, Cuzzi, Gilda, Alonzi, Tonino, Nicastri, Emanuele, Gualano, Gina, Palmieri, Fabrizio, Piacentini, Mauro, and Goletti, Delia

Subjects
MONONUCLEAR leukocytes, TH1 cells, NECROSIS, CYSTEAMINE, FLOW cytometry, CELL survival
Abstract

Objective: Cysteamine, a drug approved to treat cystinosis, has been proposed as a host-directed therapy for M. tuberculosis (Mtb) and SARS-CoV-2. The impact of cysteamine on the immune responses has not been fully investigated. We aimed to in vitro evaluate the immunomodulatory effects of cysteamine on peripheral blood mononuclear cells (PBMCs) using the purified protein derivative (PPD) as a recall antigen, and an unspecific stimulus as staphylococcal enterotoxin B (SEB). Methods: PBMCs isolated from subjects with tuberculosis infection (TBI), those with tuberculosis disease (TB), and healthy controls (HC) were in vitro stimulated with PPD or SEB and treated or not with cysteamine at different concentrations (50 µM–400 µM) for 6 hours (h) and 24 h. We evaluated the T helper1 (Th1) and T cytotoxic1 (Tc1) cell cytokine production by flow cytometry and immune-enzymatic assays. In HC, we also evaluated apoptosis and/or necrosis by flow cytometry. Results: We observed an immunomodulatory effect of cysteamine at 400 µM in PBMCs from TB and TBI subjects. It significantly reduced PPD-specific Th1 responses at 24 h and at 6 h (p=0.0004 and p=0.0009, respectively), and a similar non-significant trend was observed with cysteamine at 200 µM (p=0.06 at 24 h and p=0.14 at 6 h). Moreover, cysteamine at both 400 µM (p<0.0001 and p=0.0187 at 24 h, respectively, and p<0.0001 at 6 h for both) and 200 µM (p=0.0119 and p=0.0028 at 24 h and p=0.0028 and p=0.0003 at 6 h, respectively) significantly reduced SEB-induced Th1 and Tc1 responses. Furthermore, we found that cysteamine induced morphological lymphocyte changes and significantly reduced the lymphocyte percentage in a dose- and time-dependent manner. Cysteamine at 400 µM induced 8% late apoptosis and 1.6% necrosis (p<0.05) at 24 h. In contrast, despite significant differences from untreated conditions (p<0.05), cysteamine at 400 µM for 6 h induced approximately 1% late apoptosis and 0.1% necrosis in the cells. Conclusions: High doses of cysteamine in vitro reduce the percentages of PPD- and SEB-induced Th1 and Tc1 cells and induce late apoptosis and necrosis. Differently, cysteamine at lower doses retains the immunomodulatory effect without affecting cell viability. These findings suggest cysteamine as a potential adjunct to antimicrobial regimens as in the TB or COVID-19 field, for its ability to reduce the inflammatory status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Author

Agrati, Chiara, Castilletti, Concetta, Goletti, Delia, Sacchi, Alessandra, Bordoni, Veronica, Mariotti, Davide, Notari, Stefania, Matusali, Giulia, Meschi, Silvia, Petrone, Linda, Aiello, Alessandra, Najafi Fard, Saeid, Farroni, Chiara, Colavita, Francesca, Lapa, Daniele, Leone, Sara, Agresta, Alessandro, Capobianchi, Maria, Ippolito, Giuseppe, Vaia, Francesco, and Puro, Vincenzo

Published
2022
Full Text
View/download PDF

26. Evaluation of the Local and Peripheral Immune Responses in Patients with Cystic Echinococcosis

Author

Petrone, Linda, primary, Najafi-Fard, Saeid, additional, Falasca, Laura, additional, Sbarra, Settimia, additional, Teggi, Antonella, additional, Nicastri, Emanuele, additional, Grillo, Lucia Rosalba, additional, Burocchi, Mirco, additional, Ettorre, Giuseppe Maria, additional, Ludovisi, Alessandra, additional, Colombo, Daniele, additional, Del Nonno, Franca, additional, and Goletti, Delia, additional

Published
2024
Full Text
View/download PDF

28. World Tuberculosis Day 2024 theme “Yes! We can end TB” can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease

Author

Goletti, Delia, primary, Al-Abri, Seif, additional, Migliori, Giovanni Battista, additional, Arlehamn, Cecilia Lindestam, additional, Haldar, Pranabashis, additional, Sundling, Christopher, additional, da Costa, Christopher, additional, To, Kin Wang, additional, Martineau, Adrian R., additional, Petersen, Eskild, additional, Zumla, Alimuddin, additional, and Shan Lee, Shui, additional

Published
2024
Full Text
View/download PDF

35. C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay

Author

Russomando, Graciela, Sanabria, Diana, Díaz Acosta, Chyntia Carolina, Rojas, Leticia, Franco, Laura, Arenas, Rossana, Delogu, Giovanni, Ndiaye, Mame Diarra Bousso, Bayaa, Rim, Rakotosamimanana, Niaina, Goletti, Delia, Hoffmann, Jonathan, Delogu, Giovanni (ORCID:0000-0003-0182-8267), Russomando, Graciela, Sanabria, Diana, Díaz Acosta, Chyntia Carolina, Rojas, Leticia, Franco, Laura, Arenas, Rossana, Delogu, Giovanni, Ndiaye, Mame Diarra Bousso, Bayaa, Rim, Rakotosamimanana, Niaina, Goletti, Delia, Hoffmann, Jonathan, and Delogu, Giovanni (ORCID:0000-0003-0182-8267)

Abstract

Introduction New diagnostic tools are needed to rapidly assess the efficacy of pulmonary tuberculosis (PTB) treatment. The aim of this study was to evaluate several immune biomarkers in an observational and cross-sectional cohort study conducted in Paraguay. Methods Thirty-two patients with clinically and microbiologically confirmed PTB were evaluated before starting treatment (T0), after 2 months of treatment (T1) and at the end of treatment (T2). At each timepoint plasma levels of IFN-y, 17 pro- and anti-inflammatory cytokines/chemokines and complement factors C1q, C3 and C4 were assessed in unstimulated and Mtb-specific stimulated whole blood samples using QuantiFERON-TB gold plus and recombinant Mycobacterium smegmatis heparin binding hemagglutinin (rmsHBHA) as stimulation antigen. Complete blood counts and liver enzyme assays were also evaluated and correlated with biomarker levels in plasma. Results In unstimulated plasma, C1q (P<0.001), C4 (P<0.001), hemoglobin (P<0.001), lymphocyte proportion (P<0.001) and absolute white blood cell count (P=0.01) were significantly higher in PTB patients at baseline than in cured patients. C1q and C4 levels were found to be related to Mycobacterium tuberculosis load in sputum. Finally, a combinatorial analysis identified a plasma host signature comprising the detection of C1q and IL-13 levels in response to rmsHBHA as a tool differentiating PTB patients from cured TB profiles, with an AUC of 0.92 (sensitivity 94% and specificity 79%). Conclusion This observational study provides new insights on host immune responses throughout anti-TB treatment and emphasizes the role of host C1q and HBHA-specific IL-13 response as surrogate plasma biomarkers for monitoring TB treatment efficacy.

Published
2024

36. Characterization of the Monkeypox Virus [MPX]-Specific Immune Response in MPX-Cured Individuals Using Whole Blood to Monitor Memory Response.

Author

Petruccioli, Elisa, Sbarra, Settimia, Vita, Serena, Salmi, Andrea, Cuzzi, Gilda, De Marco, Patrizia, Matusali, Giulia, Navarra, Assunta, Pierelli, Luca, Grifoni, Alba, Sette, Alessandro, Maggi, Fabrizio, Nicastri, Emanuele, and Goletti, Delia

Subjects
ZOONOSES, MONKEYPOX, VACCINATION status, SMALLPOX vaccines, VACCINIA
Abstract

Background: Monkeypox (Mpox) is a zoonotic disease caused by monkeypox virus (MPXV), an Orthopoxvirus (OPXV). Since we are observing the first MPXV outbreak outside the African continent, the general population probably does not have a pre-existing memory response for MPXV but may have immunity against the previous smallpox vaccine based on a live replicating Vaccinia strain (VACV). Using a whole blood platform, we aim to study the MPXV- T-cell-specific response in Mpox-cured subjects. Methods: We enrolled 16 subjects diagnosed with Mpox in the previous 3–7 months and 15 healthy donors (HD) with no recent vaccination history. Whole blood was stimulated overnight with MPXV and VACV peptides to elicit CD4 and CD8 T-cell-specific responses, which were evaluated by ELISA and multiplex assay. Results: Mpox-cured subjects showed a significant IFN-γ T-cell response to MPXV and VACV. Besides IFN-γ, IL-6, IP-10, IL-8, IL-2, G-CSF, MCP-1, MIP1-α, MIP-1β, IL-1Rα, and IL-5 were significantly induced after specific stimulation compared to the unstimulated control. The specific response was mainly induced by the CD4 peptides MPX-CD4-E and VACV-CD4. Conclusions: We showed that MPXV-specific responses have a mixed Th1- and Th2-response in a whole blood platform assay, which may be useful for monitoring the specific immunity induced by vaccination or infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination.

Author

Aiello, Alessandra, Ruggieri, Serena, Navarra, Assunta, Tortorella, Carla, Vanini, Valentina, Haggiag, Shalom, Prosperini, Luca, Cuzzi, Gilda, Salmi, Andrea, Quartuccio, Maria Esmeralda, Altera, Anna Maria Gerarda, Meschi, Silvia, Matusali, Giulia, Vita, Serena, Galgani, Simonetta, Maggi, Fabrizio, Nicastri, Emanuele, Gasperini, Claudio, and Goletti, Delia

Subjects
BOOSTER vaccines, BREAKTHROUGH infections, COVID-19 vaccines, ANTIBODY formation, T cells
Abstract

This study investigated the incidence and severity of SARS-CoV-2 breakthrough infections (BIs) and the time to swab reversion in patients with multiple sclerosis (PwMS) after the booster dose of COVID-19 mRNA vaccines. We enrolled 64 PwMS who had completed the three-dose mRNA vaccine schedule and had never experienced COVID-19 before. Among the 64 PwMS, 43.8% had BIs with a median time since the third vaccine dose of 155 days. BIs occurred more frequently in ocrelizumab-treated patients (64.7%). Patients with a relapsing-remitting MS course showed a reduced incidence of BIs compared with those with a primary-progressive disease (p = 0.002). Having anti-receptor-binding domain (RBD) antibodies represented a protective factor reducing the incidence of BIs by 60% (p = 0.042). The majority of BIs were mild, and the only severe COVID-19 cases were reported in patients with a high Expanded Disability Status Scale score (EDSS > 6). The median time for a negative swab was 11 days. Notably, fingolimod-treated patients take longer for a swab-negativization (p = 0.002). Conversely, having anti-RBD antibodies ≥ 809 BAU/mL and an IFN-γ-specific T cell response ≥ 16 pg/mL were associated with a shorter time to swab-negativization (p = 0.051 and p = 0.018, respectively). In conclusion, the immunological protection from SARS-CoV-2 infection may differ among PwMS according to DMTs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study

Author

Chedid, Carole, Kokhreidze, Eka, Tukvadze, Nestani, Banu, Sayera, Uddin, Mohammad Khaja Mafij, Biswas, Samanta, Russomando, Graciela, Acosta, Chyntia Carolina Díaz, Arenas, Rossana, Ranaivomanana, Paulo PR., Razafimahatratra, Crisca, Herindrainy, Perlinot, Rakotosamimanana, Niaina, Hamze, Monzer, Ismail, Mohamad Bachar, Bayaa, Rim, Berland, Jean-Luc, Delogu, Giovanni, Endtz, Hubert, Ader, Florence, Goletti, Delia, and Hoffmann, Jonathan

Published
2020
Full Text
View/download PDF

40. Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients

Author

Lubbers, Rosalie, Sutherland, Jayne S., Goletti, Delia, de Paus, Roelof A., Dijkstra, Douwe J., van Moorsel, Coline H.M., Veltkamp, Marcel, Vestjens, Stefan M.T., Bos, Willem J.W., Petrone, Linda, Malherbe, Stephanus T., Walzl, Gerhard, Gelderman, Kyra A., Groeneveld, Geert H., Geluk, Annemieke, Ottenhoff, Tom H.M., Joosten, Simone A., and Trouw, Leendert A.

Published
2020
Full Text
View/download PDF

41. Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries

Author

Al Abri, Seif, Kasaeva, Thereza, Migliori, Giovanni Battista, Goletti, Delia, Zenner, Dominik, Denholm, Justin, Al Maani, Amal, Cirillo, Daniela Maria, Schön, Thomas, Lillebæk, Troels, Al-Jardani, Amina, Go, Un-Yeong, Dias, Hannah Monica, Tiberi, Simon, Al Yaquobi, Fatma, Khamis, Faryal Ali, Kurup, Padmamohan, Wilson, Michael, Memish, Ziad, Al Maqbali, Ali, Akhtar, Muhammad, Wejse, Christian, and Petersen, Eskild

Published
2020
Full Text
View/download PDF

42. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases

Author

Goletti, Delia, Navarra, Assunta, Petruccioli, Elisa, Cimaglia, Claudia, Compagno, Mirko, Cuzzi, Gilda, De Carli, Gabriella, Fondaco, Laura, Franzetti, Fabio, Giannetti, Alberto, Gori, Andrea, Lapadula, Giuseppe, Lichtner, Miriam, Mastroianni, Claudio M., Mazzotta, Valentina, Orchi, Nicoletta, Pavone, Paolo, Piacentini, Daniela, Pirriatore, Veronica, Pontali, Emanuele, Sarmati, Loredana, Spolti, Anna, Tacconelli, Evelina, Galli, Massimo, Antinori, Andrea, Calcagno, Andrea, and Girardi, Enrico

Published
2020
Full Text
View/download PDF

43. C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay

Author

Russomando, Graciela, primary, Sanabria, Diana, additional, Díaz Acosta, Chyntia Carolina, additional, Rojas, Leticia, additional, Franco, Laura, additional, Arenas, Rossana, additional, Delogu, Giovanni, additional, Ndiaye, Mame Diarra Bousso, additional, Bayaa, Rim, additional, Rakotosamimanana, Niaina, additional, Goletti, Delia, additional, and Hoffmann, Jonathan, additional

Published
2024
Full Text
View/download PDF

44. Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report

Author

Vita, Serena, primary, D’Abramo, Alessandra, additional, Coppola, Andrea, additional, Farroni, Chiara, additional, Iori, Anna Paola, additional, Faraglia, Francesca, additional, Sette, Alessandro, additional, Grifoni, Alba, additional, Lindestam Arlehamn, Cecilia, additional, Bibas, Michele, additional, Goletti, Delia, additional, and Nicastri, Emanuele, additional

Published
2024
Full Text
View/download PDF

45. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Author

Tortorella, Carla, Aiello, Alessandra, Gasperini, Claudio, Agrati, Chiara, Castilletti, Concetta, Ruggieri, Serena, Meschi, Silvia, Matusali, Giulia, Colavita, Francesca, Farroni, Chiara, Cuzzi, Gilda, Cimini, Eleonora, Tartaglia, Eleonora, Vanini, Valentina, Prosperini, Luca, Haggiag, Shalom, Galgani, Simona, Quartuccio, Maria Esmeralda, Salmi, Andrea, Repele, Federica, Gerarda Altera, Anna Maria, Cristofanelli, Flavia, DʼAbramo, Alessandra, Bevilacqua, Nazario, Corpolongo, Angela, Puro, Vincenzo, Vaia, Francesco, Capobianchi, Maria Rosaria, Ippolito, Giuseppe, Nicastri, Emanuele, and Goletti, Delia

Published
2021
Full Text
View/download PDF

46. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020

Author

Migliori, Giovanni Battista, Thong, Pei Min, Akkerman, Onno, Alffenaar, Jan-Willem, Alvarez-Navascues, Fernando, Assao-Neino, Mourtala Mohamed, Bernard, Pascale Valerie, Biala, Joshua Sorba, Blanc, Francois-Xavier, Bogorodskaya, Elena M., Borisov, Sergey, Buonsenso, Danilo, Calnan, Marianne, Castellotti, Paola Francesca, Centis, Rosella, Chakaya, Jeremiah Muhwa, Cho, Jin-Gun, Codecasa, Luigi Ruffo, D'Ambrosio, Lia, Denholm, Justin, Enwerem, Martin, Ferrarese, Maurizio, Galvao, Tatiana, Garcia-Clemente, Maria, Garcia-Garcia, Jose-Maria, Gualano, Gina, Gullon-Blanco, Jose Antonio, Inwentarz, Sandra, Ippolito, Giuseppe, Kunst, Heinke, Maryandyshev, Andrei, Melazzini, Mario, Mello, Fernanda Carvalho de Queiroz, Munoz-Torrico, Marcela, Njungfiyini, Patrick Bung, Palmero, Domingo Juan, Palmieri, Fabrizio, Piccioni, Pavilio, Piubello, Alberto, Rendon, Adrian, Sabria, Josefina, Saporiti, Matteo, Scognamiglio, Paola, Sharma, Samridhi, Silva, Denise Rossato, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Tabernero, Eva, Tadolini, Marina, Tchangou, Michel Eke, Thornton, Alice Boi Yatta, Tiberi, Simon, Udwadia, Zarir F., Sotgiu, Giovanni, Ong, Catherine Wei Min, and Goletti, Delia

Subjects
Ambulatory care facilities -- Statistics -- Safety and security measures -- International aspects, Tuberculosis -- Statistics -- Care and treatment -- International aspects, COVID-19 -- International aspects -- Influence, Health
Abstract

The coronavirus disease (COVID-19) pandemic has affected clinical management of tuberculosis (TB) and TB-related services (2,2). Reports of the first cohorts of patients with COVID-19 and TB have been recently [...]

Published
2020
Full Text
View/download PDF

48. Multi-omics approach to COVID-19: a domain-based literature review

Author

Montaldo, Chiara, Messina, Francesco, Abbate, Isabella, Antonioli, Manuela, Bordoni, Veronica, Aiello, Alessandra, Ciccosanti, Fabiola, Colavita, Francesca, Farroni, Chiara, Najafi Fard, Saeid, Giombini, Emanuela, Goletti, Delia, Matusali, Giulia, Rozera, Gabriella, Rueca, Martina, Sacchi, Alessandra, Piacentini, Mauro, Agrati, Chiara, Fimia, Gian Maria, Capobianchi, Maria Rosaria, Lauria, Francesco Nicola, and Ippolito, Giuseppe

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results